Connor, Clark & Lunn Investment Management Ltd. Pacira Bio Sciences, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $26 Billion
- Q2 2025
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 214,690 shares of PCRX stock, worth $4.94 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
214,690
Previous 171,377
25.27%
Holding current value
$4.94 Million
Previous $4.26 Million
20.5%
% of portfolio
0.02%
Previous 0.02%
Shares
10 transactions
Others Institutions Holding PCRX
# of Institutions
261Shares Held
51MCall Options Held
289KPut Options Held
130K-
Black Rock Inc. New York, NY8.01MShares$184 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.41MShares$124 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.4MShares$55.1 Million0.08% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.25MShares$51.9 Million0.04% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.15MShares$49.5 Million0.01% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.05B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...